Iranian specialists' approach to treatment escalation in multiple sclerosis patients with cognitive impairment
Copyright © 2023 Iranian Neurological Association, and Tehran University of Medical Sciences Published by Tehran University of Medical Sciences..
Background: People with multiple sclerosis (MS) and their physicians recognize cognitive retention as an important desired outcome of disease-modifying therapies (DMTs). In this study, we attempted to gather the opinions of Iranian MS experts regarding the treatment approach toward clinical cases with different physical and cognitive conditions. Methods: Opinions of 20 MS specialists regarding the best approach to 6 case scenarios (with different clinical, cognitive, and imaging characteristics) were gathered via a form. Results: The estimated kappa of 0.16 [95% confidence interval (CI): 0.159-0.163; P < 0.001] suggested a poor degree of agreement on the treatment choice among the professionals. Conclusion: Although most specialists agreed with treatment escalation in cases with cognitive impairment, there was no general agreement. Furthermore, there was not enough clinical evidence in the literature to develop consensus guidelines on the matter.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Current journal of neurology - 22(2023), 1 vom: 05. Jan., Seite 1-7 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ghadiri, Fereshteh [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cognitive Dysfunction |
|---|
| Anmerkungen: |
Date Revised 29.11.2023 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.18502/cjn.v22i1.12610 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365025437 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365025437 | ||
| 003 | DE-627 | ||
| 005 | 20231226100810.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.18502/cjn.v22i1.12610 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1216.xml |
| 035 | |a (DE-627)NLM365025437 | ||
| 035 | |a (NLM)38011357 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ghadiri, Fereshteh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Iranian specialists' approach to treatment escalation in multiple sclerosis patients with cognitive impairment |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 29.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2023 Iranian Neurological Association, and Tehran University of Medical Sciences Published by Tehran University of Medical Sciences. | ||
| 520 | |a Background: People with multiple sclerosis (MS) and their physicians recognize cognitive retention as an important desired outcome of disease-modifying therapies (DMTs). In this study, we attempted to gather the opinions of Iranian MS experts regarding the treatment approach toward clinical cases with different physical and cognitive conditions. Methods: Opinions of 20 MS specialists regarding the best approach to 6 case scenarios (with different clinical, cognitive, and imaging characteristics) were gathered via a form. Results: The estimated kappa of 0.16 [95% confidence interval (CI): 0.159-0.163; P < 0.001] suggested a poor degree of agreement on the treatment choice among the professionals. Conclusion: Although most specialists agreed with treatment escalation in cases with cognitive impairment, there was no general agreement. Furthermore, there was not enough clinical evidence in the literature to develop consensus guidelines on the matter | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cognitive Dysfunction | |
| 650 | 4 | |a Iran | |
| 650 | 4 | |a Multiple Sclerosis | |
| 650 | 4 | |a Specialist | |
| 650 | 4 | |a Treatment Escalation | |
| 700 | 1 | |a Asadollahzadeh, Elnaz |e verfasserin |4 aut | |
| 700 | 1 | |a Ebadi, Zahra |e verfasserin |4 aut | |
| 700 | 1 | |a Sahraian, Mohammad Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Azimi, Amirreza |e verfasserin |4 aut | |
| 700 | 1 | |a Navardi, Samira |e verfasserin |4 aut | |
| 700 | 1 | |a Heidari, Hora |e verfasserin |4 aut | |
| 700 | 1 | |a Abna, Zohreh |e verfasserin |4 aut | |
| 700 | 1 | |a Aboutorabi, Marzieh |e verfasserin |4 aut | |
| 700 | 1 | |a Adibi, Iman |e verfasserin |4 aut | |
| 700 | 1 | |a Baghbanian, Seyed Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Paybast, Sepideh |e verfasserin |4 aut | |
| 700 | 1 | |a Poursadeghfard, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Hosseini, Samaneh |e verfasserin |4 aut | |
| 700 | 1 | |a Shahmohammadi, Sareh |e verfasserin |4 aut | |
| 700 | 1 | |a Ghaffari, Mehran |e verfasserin |4 aut | |
| 700 | 1 | |a Ghalyanchi-Langroodi, Hamidreza |e verfasserin |4 aut | |
| 700 | 1 | |a Ghiasian, Masoud |e verfasserin |4 aut | |
| 700 | 1 | |a Kamali, Hoda |e verfasserin |4 aut | |
| 700 | 1 | |a Kouchaki, Ebrahim |e verfasserin |4 aut | |
| 700 | 1 | |a Mahrabi, Farzad |e verfasserin |4 aut | |
| 700 | 1 | |a Mohammadianinejad, Ehsan |e verfasserin |4 aut | |
| 700 | 1 | |a Nahayati, Mohammad Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Moghadasi, Abdorreza Naser |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current journal of neurology |d 2020 |g 22(2023), 1 vom: 05. Jan., Seite 1-7 |w (DE-627)NLM365025208 |x 2717-011X |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2023 |g number:1 |g day:05 |g month:01 |g pages:1-7 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.18502/cjn.v22i1.12610 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2023 |e 1 |b 05 |c 01 |h 1-7 | ||